Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Pharmaceuticals · 22.04.2025 · 18 (5) · 607
DOI: 10.3390/ph18050607 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.04.2025. Verfasst von Masaru Tanaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Danube Neuroscience Research Laboratory, HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), T…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 457 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development, and Innovation Office, SZTE SZAOK-KKA, HUN-REN Hungarian Research Network.
Abstract (Originalsprache)
Background
Quinoline-derived metabolites exhibit notable chemical complexity. What causes minor structural alterations to induce significant changes in disease outcomes? Historically, eclipsed by more straightforward scaffolds, these chemicals serve as a dynamic hub in tryptophan metabolism, linking immunomodulation, excitotoxicity, and cancer. However, many of these compounds struggle to cross the blood–brain barrier, and we still do not fully understand how certain structural changes affect their bioavailability or off-target effects. Thus, contemporary research highlights halogenation, esterification, and computational modeling to enhance structure–activity relationships. Summary: This narrative review emphasizes the integration of rational drug design, multi-target ligands, and prodrug methods in enhancing quinoline scaffolds. We explore each molecule’s therapeutic promise, refine each scaffold’s design, and develop each derivative to maximize clinical utility. Translating these laboratory findings into clinical practice, however, remains a formidable challenge.
Conclusions
Through the synthesis of findings regarding NMDA receptor antagonism, improved oral bioavailability, and reduced metabolic instability, we demonstrate how single-site changes might modulate excitotoxicity and immunological signaling. Advancing quinoline-based medicines will yield significant advancements in neurology, psychiatry, and oncology. This enlarged framework fosters collaborative discovery, engages various audiences, and advances the field towards next-generation disease-modifying therapies. Robust preclinical validation, patient classification, and comprehensive toxicity evaluations are crucial stages for achieving these extensive endeavors and fostering future therapeutic discoveries globally.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Danube Neuroscience Research Laboratory, HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Tisza Lajos krt. 113, H-6725 Szeged, Hungary.
- Institute of Pharmaceutical Chemistry and HUN-REN-SZTE Stereochemistry Research Group, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.
- Department of Neurology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary.
ORCID-Profile: Masaru Tanaka, István Szatmári
Förderung
- National Research, Development, and Innovation Office
- SZTE SZAOK-KKA
- HUN-REN Hungarian Research Network
- National Research, Development, and Innovation Office—NKFIH
Zitieren
APA
Tanaka, M., Szatmári, I., & Vécsei, L. (2025). Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design. Pharmaceuticals, 18(5), 607. https://doi.org/10.3390/ph18050607
Vancouver
Tanaka M, Szatmári I, Vécsei L. Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design. Pharmaceuticals. 2025;18(5):607. doi:10.3390/ph18050607
BibTeX
@article{Tanaka2025,
author = {Tanaka, Masaru and Szatmári, István and Vécsei, László},
title = {Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {5},
pages = {607},
doi = {10.3390/ph18050607}
}
EUVIMED